Full Press Release Details
Clinical Findings Published in Scientific Journal Nature
LIXTE's Ongoing Ovarian and Colorectal Cancer Trials
Indicates that Inhibition of PP2A Enhances Immunotherapy Response
LIXTE's Proprietary Compound LB100
Calif., July 9, 2025-LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq:
LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that the medical journal Nature has published findings
by a team of physician-scientists that validate LIXTE's ongoing clinical trials with its proprietary compound LB100 for Ovarian
and Colorectal cancers (https://www.nature.com/articles/s41586-025-09203-8).
team led by principal investigator Amir Jazaeri, MD, professor of Gynecologic Oncology and Reproductive Medicine at The University of
Texas MD Anderson Cancer Center, studied survival outcomes of Ovarian Clear Cell Carcinoma (OCCC) patients treated with immune checkpoint
blockade therapy (clinicaltrials.gov identifier: NCT03026062). The ;study showed that patients having tumors with inactivating mutations
in PPP2R1A - the major scaffold subunit of protein phosphatase 2A (PP2A) - had significantly better overall survival, compared with patients
who did not have this mutation in their tumors.
mutations in PPP2R1A are known to reduce the enzymatic activity of PP2A, which is the target of LIXTE's lead compound LB-100. Tumors
with mutations in PPP2R1A were found to have increased the interferon gamma response pathway, which is known to be associated with improved
immune checkpoint responses.
is currently investigating the activity of LB-100 in combination with checkpoint immunotherapy in two clinical trials. The first is enrolling
patients with OCCC, led by Dr. Jazaeri at MD Anderson Cancer Center, and also is open at Northwester University. In this trial, LIXTE
is collaborating with GSK to test LB-100 in combination with dostarlimab (anti PD1). In the second trial, at the Netherlands Cancer Institute,
LIXTE is collaborating with Roche to test LB-100 in combination with atezolizumab (anti PDL1) in colon cancer patients.
only did we identify a new biomarker for improved survival with immunotherapy in ovarian cancer, but we also confirmed the correlation
of this biomarker with survival benefit in other cancer types," said Dr. Jazaeri, who was co-senior author of the Nature
article. "Since PPP2R1A mutations are relatively uncommon, we believe the same benefits may be possible by targeting the PPP2A
pathway using drugs, which we currently are evaluating in a clinical trial at MD Anderson."
van der Baan, LIXTE's Chief Scientific Officer, added, "This work extends a body of pre-clinical evidence indicating that
LB-100 is strongly synergistic with checkpoint immunotherapy in a range of cancer types. We look forward to the first results of our
clinical studies in the second half of this year."
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality -
that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Additional information about LIXTE can be found at www.lixte.com.
Statement Disclaimer
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal
costs to protect and maintain the Company's intellectual property worldwide, and the Company's ability to obtain and maintain
compliance with Nasdaq's continued listing requirements, are all forward-looking statements. These statements are generally accompanied
by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology.
Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have
been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general
are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission
at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
more information about LIXTE, Contact:
more information about LIXTE, Contact: info@lixte.com
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations pwinvestor@pondel.com
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962